In China, pharmaceutical plants must undergo Good Manufacturing Practice (GMP) re-certification every five years. This ensures continuous compliance with evolving standards. The National Medical Products Administration (NMPA) conducts these inspections, evaluating facilities, processes, and quality control measures to guarantee the safety and efficacy of manufactured drugs.
